• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Part D Premiums Will Be Slightly Lower in 2023: CMS

Article

CMS says the average premium in 2023 will 1.8% lower than this year's average premium.

Inflation is affecting many parts of the economy, but CMS announced Friday that Medicare Part D premiums may become slightly less expensive in 2023.

Based on plan bids so far, the average basic monthly premium in 2023 is expected to be $31.50, according to the CMS announcement. That is 1.8% decrease from the average monthly premium this year, which is $32.08.

That wasn’t the only good news about prescription drug costs for Medicare beneficiaries this week. The legislative package negotiated by Sen. Joe Manchin III, a West Virginia Democrat, and Senate Majority Leader Chuck Schumer includes several provisions that will save beneficiaries.

The legislation would cap Part D out-of-pocket costs at $2,000 a year and impose a rebate on drug prices that manufacturers raise above the rate of inflation.

The bill, which must be approved by the House and signed by President Biden before it becomes law, would also empower CMS to negotiate drug prices for the first time.

Related Videos
Video 4 - "Diabetes Prevention and Reducing Disparities Across Populations"
Video 3 - "Integrating CGMs into Diabetes Treatment Programs"
Video 2 - "Identifying Inequities in CGM Access"
Video 1 - "Challenges in Treating High-Risk Patients With Diabetes"
Video 17 - "Insights on Plan Enhancements & Fertility Care Innovations"
Video 16 - "Mitigating Risks: How Fertility Benefits Safeguard Employee Health"
Video 15 - "Strategic Investment: Fertility Benefits and Positive Employee Outcomes"
"Supporting Employee Wellbeing Through Fertility Benefits"
Related Content
© 2024 MJH Life Sciences

All rights reserved.